Neoplasia
Definitions and nomenclature of tumours, benign versus malignant behaviour, the molecular basis of cancer, carcinogens, routes of spread, grading and staging, and the paraneoplastic and oncological emergencies that present to the emergency department.
By the end of this page you should be able to
- Define neoplasia, dysplasia and anaplasia, and use tumour nomenclature correctly.
- Compare benign and malignant tumours.
- Describe oncogenes, tumour suppressor genes and the hallmarks of cancer.
- List chemical, physical and biological carcinogens with examples.
- Describe routes of spread, grading and staging, tumour markers, paraneoplastic syndromes and oncological emergencies.
Definitions and naming
A neoplasm is an abnormal mass of tissue whose growth is uncoordinated with that of normal tissue and persists after the stimulus that caused it has stopped. It is clonal, arising from a single cell that has acquired genetic changes.
Benign tumours add -oma to the tissue of origin: adenoma (glandular epithelium), papilloma, lipoma, leiomyoma, chondroma. Malignant epithelial tumours are carcinomas (squamous cell carcinoma, adenocarcinoma, urothelial carcinoma); malignant mesenchymal tumours are sarcomas (liposarcoma, osteosarcoma, leiomyosarcoma). Exceptions to learn: lymphoma, melanoma, mesothelioma and seminoma are malignant despite the ending. Teratomas contain tissues from more than one germ layer. A hamartoma is a disorganised mass of tissue normal to the site (lung hamartoma); a choristoma is normal tissue in the wrong place (pancreatic rest). Leukaemias are malignancies of haematopoietic cells in the blood and marrow.
Benign versus malignant
- Differentiation: benign tumours resemble their tissue of origin; malignant ones range from well differentiated to anaplastic (lack of differentiation: pleomorphism, large hyperchromatic nuclei, high nuclear to cytoplasmic ratio, abnormal mitoses, tumour giant cells).
- Rate of growth: usually slow versus usually faster.
- Local invasion: benign tumours are usually encapsulated and expansile; malignant tumours invade surrounding tissue.
- Metastasis: the definitive feature of malignancy. Benign tumours do not metastasise.
- Dysplasia: disordered growth with loss of uniformity and architectural orientation, a precursor lesion. When it involves the full thickness of the epithelium without breaching the basement membrane, it is carcinoma in situ.
- Benign tumours can still kill by site (a meningioma), hormone secretion (an insulinoma) or complications (haemorrhage, torsion).
The molecular basis
- Oncogenes: mutated or overexpressed versions of normal growth-promoting genes (proto-oncogenes); a single altered copy acts dominantly. Examples: RAS (the commonest in human cancer), MYC, HER2 (ERBB2) amplification in breast cancer, BCR-ABL fusion from the Philadelphia chromosome in chronic myeloid leukaemia, BRAF in melanoma.
- Tumour suppressor genes: brakes on growth; both copies usually need to be lost (the two-hit hypothesis, from retinoblastoma). Examples: TP53 (the guardian of the genome: halts the cell cycle or triggers apoptosis after DNA damage; mutated in about half of cancers), RB, APC (colorectal), BRCA1 and BRCA2 (DNA repair; breast, ovarian and prostate cancer).
- DNA repair genes: mismatch repair defects (Lynch syndrome) increase mutation rate.
- Hallmarks of cancer: self-sufficiency in growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replication (telomerase), sustained angiogenesis (VEGF), invasion and metastasis, altered metabolism (aerobic glycolysis, the Warburg effect), evasion of immune destruction, with genomic instability and tumour-promoting inflammation as enablers.
- Cancer develops through accumulation of mutations over time: the colorectal adenoma to carcinoma sequence is the model.
Carcinogens
- Chemical: direct-acting alkylating agents (some chemotherapy drugs, causing secondary leukaemia), and indirect agents needing metabolic activation: polycyclic hydrocarbons in tobacco smoke (lung, bladder, head and neck), aromatic amines (bladder), aflatoxin (liver), nitrosamines (stomach), asbestos (mesothelioma, lung), vinyl chloride (hepatic angiosarcoma), benzene (leukaemia).
- Radiation: ultraviolet B (pyrimidine dimers: basal cell and squamous cell carcinoma, melanoma; Australia has among the highest skin cancer rates in the world), ionising radiation (leukaemia, thyroid, breast).
- Viral: HPV (cervical, anal and oropharyngeal carcinoma; E6 and E7 proteins inactivate p53 and RB), EBV (Burkitt and Hodgkin lymphoma, nasopharyngeal carcinoma), hepatitis B and C (hepatocellular carcinoma), HHV-8 (Kaposi sarcoma), HTLV-1 (adult T cell leukaemia).
- Bacterial: Helicobacter pylori (gastric adenocarcinoma, MALT lymphoma).
- Chronic inflammation: ulcerative colitis, Barrett oesophagus, chronic osteomyelitis sinus tracts (Marjolin ulcer in old burn scars).
Spread, grade and stage
Malignant cells spread by direct invasion, lymphatics (carcinomas typically: to regional nodes first, the basis of sentinel node biopsy), blood (sarcomas and some carcinomas: to the lungs via systemic veins, to the liver via the portal vein; renal cell carcinoma and hepatocellular carcinoma invade veins) and transcoelomic seeding across body cavities (ovarian cancer in the peritoneum, lung cancer in the pleura). Tumours that commonly spread to bone: prostate, breast, lung, kidney and thyroid. Brain metastases most often come from lung, breast, melanoma, kidney and colon.
Grade is how abnormal the cells look (differentiation and mitoses); stage is how far the tumour has spread, usually by TNM (tumour size and extent, nodes, metastases). Stage predicts prognosis better than grade.
Tumour markers help monitoring more than diagnosis: PSA (prostate), CEA (colorectal), CA-125 (ovary), alpha-fetoprotein (hepatocellular carcinoma, germ cell tumours), beta-hCG (germ cell tumours, choriocarcinoma), CA 19-9 (pancreas).
Paraneoplastic syndromes and emergencies
- Hypercalcaemia of malignancy: PTH-related peptide (squamous cell carcinomas), bone metastases, calcitriol (lymphoma). Thirst, polyuria, confusion, constipation, renal impairment; treat with fluids and bisphosphonates or denosumab.
- SIADH: small cell lung cancer; hyponatraemia.
- Ectopic ACTH: small cell lung cancer; hypokalaemic alkalosis, hyperglycaemia.
- Lambert-Eaton syndrome and other neurological syndromes (cerebellar degeneration, limbic encephalitis).
- Hypercoagulability (Trousseau syndrome): migratory thrombophlebitis and VTE, especially pancreatic, lung and gastric adenocarcinoma.
- Oncological emergencies: neutropenic sepsis (antibiotics within the first hour), malignant spinal cord compression (back pain in a person with cancer; MRI the whole spine; dexamethasone), superior vena cava obstruction, tumour lysis syndrome (hyperkalaemia, hyperphosphataemia, hypocalcaemia, hyperuricaemia, AKI; after treatment of lymphomas and leukaemias), hyperviscosity, malignant pericardial effusion and tamponade, raised intracranial pressure from metastases.
Making the answer flow
- Define precisely, then compare benign with malignant in a set order: differentiation, growth, invasion, metastasis.
- Give one oncogene and one tumour suppressor with the cancer each causes.
- Link the pathology to an ED presentation: hypercalcaemia, cord compression, tumour lysis, neutropenic sepsis.
Where marks are lost
- Calling lymphoma or melanoma benign because of the "-oma".
- Saying invasion defines malignancy. Metastasis is the definitive feature; carcinoma in situ is malignant but not invasive.
- Confusing grade (how the cells look) with stage (how far it has spread).
- Using tumour markers as screening or diagnostic tests in the ED.
Where this meets the emergency department
- New back pain in a person with cancer is cord compression until imaged; do not wait for weakness.
- A febrile patient within weeks of chemotherapy is treated as neutropenic sepsis before the count is back.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Define neoplasia and compare benign and malignant tumours.
Show answer
- Abnormal, clonal, uncoordinated growth persisting after removal of the stimulus.
- Benign: well differentiated, slow, expansile, encapsulated, no metastasis.
- Malignant: variable differentiation to anaplasia, faster, invasive, metastasise.
- Benign tumours can cause harm by location, secretion or complications.
- 2.
What are oncogenes and tumour suppressor genes? Give examples.
Show answer
- Oncogenes: gain-of-function, dominant; RAS, MYC, HER2, BCR-ABL, BRAF.
- Tumour suppressors: loss-of-function, recessive at the cell level (two hits); TP53, RB, APC, BRCA1 and 2.
- Inherited one hit explains familial cancer syndromes (retinoblastoma, Li-Fraumeni, familial adenomatous polyposis).
- 3.
Describe how a carcinoma metastasises.
Show answer
- Loss of cell adhesion (E-cadherin), epithelial-mesenchymal transition.
- Degradation of basement membrane and matrix (matrix metalloproteinases); migration.
- Intravasation into lymphatics or blood vessels; survival in circulation (platelet cloaking, immune evasion).
- Extravasation and colonisation of a distant site with angiogenesis; seed and soil concept explains organ preferences.
- 4.
Name some carcinogens with the tumours they cause.
Show answer
- Tobacco: lung, head and neck, bladder, pancreas, oesophagus.
- Asbestos: mesothelioma, lung. Aflatoxin: hepatocellular. Aromatic amines: bladder. Benzene: leukaemia.
- UV: skin cancers. Ionising radiation: leukaemia, thyroid.
- Viruses: HPV, EBV, HBV, HCV, HHV-8. Bacteria: H. pylori.
- 5.
What is the difference between grade and stage?
Show answer
- Grade: histological degree of differentiation and mitotic activity (e.g. well, moderately, poorly differentiated; Gleason for prostate).
- Stage: anatomical extent (TNM: tumour, nodes, metastases).
- Stage is the stronger predictor of prognosis and guides treatment.
- 6.
What is tumour lysis syndrome?
Show answer
- Massive release of intracellular contents after rapid tumour cell death, usually after treatment of high-grade lymphomas and leukaemias, sometimes spontaneous.
- Hyperkalaemia, hyperphosphataemia, secondary hypocalcaemia, hyperuricaemia; AKI from urate and calcium phosphate precipitation.
- Arrhythmias, seizures, renal failure.
- Prevention and treatment: hydration, allopurinol or rasburicase (avoid in G6PD deficiency), treat hyperkalaemia, dialysis.
- 7.
Describe the mechanisms of hypercalcaemia in malignancy.
Show answer
- Humoral: PTH-related peptide (squamous cell carcinomas of lung, head and neck, renal, breast) acting on PTH receptors.
- Local osteolysis from bone metastases or myeloma (cytokines, RANKL).
- Calcitriol production by lymphomas.
- Rarely ectopic PTH.
- PTH is suppressed in all except the rare ectopic PTH and coexisting hyperparathyroidism.
- 8.
A woman with breast cancer presents with back pain and leg weakness. What is the likely pathology?
Show answer
- Malignant spinal cord compression: vertebral body metastasis (thoracic most common) with collapse or epidural tumour.
- Cord ischaemia and oedema from venous congestion; outcome depends on function at presentation.
- Urgent whole spine MRI, high-dose dexamethasone, radiotherapy or surgery.
- Breast, prostate, lung, kidney, myeloma commonly involved.
- 9.
What is dysplasia and why does it matter?
Show answer
- Disordered growth: pleomorphism, hyperchromasia, increased mitoses, loss of polarity and architectural orientation.
- Graded low to high; full-thickness without invasion is carcinoma in situ.
- Precursor to invasive cancer (cervix, Barrett oesophagus, colonic adenoma).
- Reversible in early stages if the stimulus is removed; the basis of screening (cervical screening test for HPV).
Practise this week
Week 7 in the other subjects
- Anatomy: Upper limb nerve and vessel injuries
- Pharmacology: Antihypertensives, nitrates and heart failure drugs
- Physiology: The cardiac cycle and pressure-volume loops
Not affiliated with the Australasian College for Emergency Medicine. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.